메뉴 건너뛰기




Volumn 27, Issue 3, 2013, Pages 341-349

Biologics in SLE: Towards new approaches

Author keywords

Biologics; SLE; Treatment

Indexed keywords

ABATACEPT; ATACICEPT; BELIMUMAB; BIOLOGICAL PRODUCT; CYCLOPHOSPHAMIDE; EPRATUZUMAB; FORIGERIMOD; PLACEBO; PREDNISONE; RITUXIMAB; TABALUMAB;

EID: 85027936575     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2013.07.006     Document Type: Review
Times cited : (25)

References (50)
  • 2
    • 13444252282 scopus 로고    scopus 로고
    • Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial
    • P.P. Sfikakis, J.N. Boletis, and S. Lionaki Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial Arthritis & Rheumatism 52 2005 501 513
    • (2005) Arthritis & Rheumatism , vol.52 , pp. 501-513
    • Sfikakis, P.P.1    Boletis, J.N.2    Lionaki, S.3
  • 3
    • 4043179907 scopus 로고    scopus 로고
    • B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
    • R.J. Looney, J.H. Anolik, and D. Campbell B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis & Rheumatism 50 2004 2580 2589
    • (2004) Arthritis & Rheumatism , vol.50 , pp. 2580-2589
    • Looney, R.J.1    Anolik, J.H.2    Campbell, D.3
  • 4
    • 34247246405 scopus 로고    scopus 로고
    • Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
    • I. Gunnarsson, B. Sundelin, T. Jonsdottir, S.H. Jacobson, E.W. Henriksson, and R.F. van Vollenhoven Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis Arthritis & Rheumatism 56 2007 1263 1272
    • (2007) Arthritis & Rheumatism , vol.56 , pp. 1263-1272
    • Gunnarsson, I.1    Sundelin, B.2    Jonsdottir, T.3    Jacobson, S.H.4    Henriksson, E.W.5    Van Vollenhoven, R.F.6
  • 7
    • 10844243750 scopus 로고    scopus 로고
    • Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
    • R.F. van Vollenhoven, I. Gunnarsson, and E. Welin-Henriksson Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone Scandinavian Journal of Rheumatology 33 2004 423 427
    • (2004) Scandinavian Journal of Rheumatology , vol.33 , pp. 423-427
    • Van Vollenhoven, R.F.1    Gunnarsson, I.2    Welin-Henriksson, E.3
  • 9
    • 84866184129 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in patients with active proliferative lupus nephritis the lupus nephritis assessment with rituximab study
    • B.H. Rovin, R. Furie, and K. Latinis Efficacy and safety of rituximab in patients with active proliferative lupus nephritis the lupus nephritis assessment with rituximab study Arthritis & Rheumatism 64 2012 1215 1226
    • (2012) Arthritis & Rheumatism , vol.64 , pp. 1215-1226
    • Rovin, B.H.1    Furie, R.2    Latinis, K.3
  • 10
    • 67650606765 scopus 로고    scopus 로고
    • Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases
    • M. Ramos-Casals, M.J. Soto, M.J. Cuadrado, and M.A. Khamashta Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases Lupus 18 2009 767 776
    • (2009) Lupus , vol.18 , pp. 767-776
    • Ramos-Casals, M.1    Soto, M.J.2    Cuadrado, M.J.3    Khamashta, M.A.4
  • 11
    • 28544449032 scopus 로고    scopus 로고
    • B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients
    • M.J. Leandro, G. Cambridge, J.C. Edwards, M.R. Ehrenstein, and D.A. Isenberg B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients Rheumatology 44 2005 1542 1545
    • (2005) Rheumatology , vol.44 , pp. 1542-1545
    • Leandro, M.J.1    Cambridge, G.2    Edwards, J.C.3    Ehrenstein, M.R.4    Isenberg, D.A.5
  • 12
    • 74849131972 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
    • J.T. Merrill, C.M. Neuwelt, and D.J. Wallace Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis & Rheumatism 62 2010 222 233
    • (2010) Arthritis & Rheumatism , vol.62 , pp. 222-233
    • Merrill, J.T.1    Neuwelt, C.M.2    Wallace, D.J.3
  • 13
    • 71049118062 scopus 로고    scopus 로고
    • Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
    • R. Pepper, M. Griffith, and C. Kirwan Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids Nephrology Dialysis Transplantation 24 2009 3717 3723
    • (2009) Nephrology Dialysis Transplantation , vol.24 , pp. 3717-3723
    • Pepper, R.1    Griffith, M.2    Kirwan, C.3
  • 14
    • 84880243381 scopus 로고    scopus 로고
    • Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
    • M.B. Condon, D. Ashby, and R.J. Pepper Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids Annals of the Rheumatic Diseases 72 2013 1280 1286
    • (2013) Annals of the Rheumatic Diseases , vol.72 , pp. 1280-1286
    • Condon, M.B.1    Ashby, D.2    Pepper, R.J.3
  • 15
    • 84857562039 scopus 로고    scopus 로고
    • Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: A steroid-sparing regimen
    • A.N. Ezeonyeji, and D.A. Isenberg Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen Rheumatology 51 2012 476 481
    • (2012) Rheumatology , vol.51 , pp. 476-481
    • Ezeonyeji, A.N.1    Isenberg, D.A.2
  • 16
    • 77957682858 scopus 로고    scopus 로고
    • The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
    • J.T. Merrill, R. Burgos-Vargas, and R. Westhovens The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial Arthritis & Rheumatism 62 2010 3077 3087
    • (2010) Arthritis & Rheumatism , vol.62 , pp. 3077-3087
    • Merrill, J.T.1    Burgos-Vargas, R.2    Westhovens, R.3
  • 17
    • 78650632504 scopus 로고    scopus 로고
    • An assessment of disease flare in patients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA
    • D.A. Isenberg, E. Allen, and V. Farewell An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA Annals of the Rheumatic Diseases 70 2011 54 59
    • (2011) Annals of the Rheumatic Diseases , vol.70 , pp. 54-59
    • Isenberg, D.A.1    Allen, E.2    Farewell, V.3
  • 18
    • 84863756711 scopus 로고    scopus 로고
    • Efficacy and safety of abatacept over 12 Months in patients with lupus nephritis: Results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study
    • R. Furie, K. Nicholls, and T.T. Cheng Efficacy and safety of abatacept over 12 Months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study Arthritis & Rheumatism 63 2011 S962 S983
    • (2011) Arthritis & Rheumatism , vol.63
    • Furie, R.1    Nicholls, K.2    Cheng, T.T.3
  • 19
    • 84868126198 scopus 로고    scopus 로고
    • Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions
    • D. Wofsy, J.L. Hillson, and B. Diamond Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions Arthritis & Rheumatism 64 2012 3660 3665
    • (2012) Arthritis & Rheumatism , vol.64 , pp. 3660-3665
    • Wofsy, D.1    Hillson, J.L.2    Diamond, B.3
  • 20
    • 45349102050 scopus 로고    scopus 로고
    • Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index
    • M. Petri, N. Kasitanon, and S.S. Lee Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index Arthritis & Rheumatism 58 2008 1784 1788
    • (2008) Arthritis & Rheumatism , vol.58 , pp. 1784-1788
    • Petri, M.1    Kasitanon, N.2    Lee, S.S.3
  • 21
    • 45349106761 scopus 로고    scopus 로고
    • Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response
    • M. Petri, N. Kasitanon, and S. Singh Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response Arthritis & Rheumatism 58 2008 1789 1795
    • (2008) Arthritis & Rheumatism , vol.58 , pp. 1789-1795
    • Petri, M.1    Kasitanon, N.2    Singh, S.3
  • 22
    • 0028483990 scopus 로고
    • Treatment of murine lupus with CTLA4Ig
    • B.K. Finck, P.S. Linsley, and D. Wofsy Treatment of murine lupus with CTLA4Ig Science 265 1994 1225 1227
    • (1994) Science , vol.265 , pp. 1225-1227
    • Finck, B.K.1    Linsley, P.S.2    Wofsy, D.3
  • 23
    • 77950238639 scopus 로고    scopus 로고
    • Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases
    • S. Lee, and M. Ballow Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases The Journal of Allergy and Clinical Immunology 125 2010 814 820
    • (2010) The Journal of Allergy and Clinical Immunology , vol.125 , pp. 814-820
    • Lee, S.1    Ballow, M.2
  • 24
    • 0242495115 scopus 로고    scopus 로고
    • Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
    • K.P. Baker, B.M. Edwards, and S.H. Main Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator Arthritis and Rheumatism 48 2003 3253 3265
    • (2003) Arthritis and Rheumatism , vol.48 , pp. 3253-3265
    • Baker, K.P.1    Edwards, B.M.2    Main, S.H.3
  • 25
    • 69749120918 scopus 로고    scopus 로고
    • A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
    • D.J. Wallace, W. Stohl, and R.A. Furie A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus Arthritis and Rheumatism 61 2009 1168 1178
    • (2009) Arthritis and Rheumatism , vol.61 , pp. 1168-1178
    • Wallace, D.J.1    Stohl, W.2    Furie, R.A.3
  • 26
    • 84875947710 scopus 로고    scopus 로고
    • Belimumab for systemic lupus erythematosus: A practice-based view
    • I. Parodis, M. Axelsson, and I. Gunnarsson Belimumab for systemic lupus erythematosus: a practice-based view Lupus 22 2013 372 380
    • (2013) Lupus , vol.22 , pp. 372-380
    • Parodis, I.1    Axelsson, M.2    Gunnarsson, I.3
  • 27
    • 79952070370 scopus 로고    scopus 로고
    • Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial
    • S.V. Navarra, R.M. Guzman, and A.E. Gallacher Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 2011 721 731
    • (2011) Lancet , vol.377 , pp. 721-731
    • Navarra, S.V.1    Guzman, R.M.2    Gallacher, A.E.3
  • 28
    • 82455198794 scopus 로고    scopus 로고
    • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
    • R. Furie, M. Petri, and O. Zamani A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis and Rheumatism 63 2011 3918 3930
    • (2011) Arthritis and Rheumatism , vol.63 , pp. 3918-3930
    • Furie, R.1    Petri, M.2    Zamani, O.3
  • 30
    • 84862002288 scopus 로고    scopus 로고
    • Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
    • W. Stohl, F. Hiepe, and K.M. Latinis Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus Arthritis and Rheumatism 64 2012 2328 2337
    • (2012) Arthritis and Rheumatism , vol.64 , pp. 2328-2337
    • Stohl, W.1    Hiepe, F.2    Latinis, K.M.3
  • 31
    • 84867398973 scopus 로고    scopus 로고
    • Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials
    • S. Manzi, J. Sanchez-Guerrero, and J.T. Merrill Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials Annals of the Rheumatic Diseases 71 2012 1833 1838
    • (2012) Annals of the Rheumatic Diseases , vol.71 , pp. 1833-1838
    • Manzi, S.1    Sanchez-Guerrero, J.2    Merrill, J.T.3
  • 32
    • 84863850571 scopus 로고    scopus 로고
    • Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response
    • R.F. van Vollenhoven, M.A. Petri, and R. Cervera Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response Annals of the Rheumatic Diseases 71 2012 1343 1349
    • (2012) Annals of the Rheumatic Diseases , vol.71 , pp. 1343-1349
    • Van Vollenhoven, R.F.1    Petri, M.A.2    Cervera, R.3
  • 33
    • 84871574493 scopus 로고    scopus 로고
    • Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE
    • M.A. Dooley, F. Houssiau, and C. Aranow Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE Lupus 22 2013 63 72
    • (2013) Lupus , vol.22 , pp. 63-72
    • Dooley, M.A.1    Houssiau, F.2    Aranow, C.3
  • 34
    • 84897996554 scopus 로고    scopus 로고
    • Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
    • V. Strand, R.A. Levy, and R. Cervera Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials Annals of the Rheumatic Diseases 2013
    • (2013) Annals of the Rheumatic Diseases
    • Strand, V.1    Levy, R.A.2    Cervera, R.3
  • 35
    • 84872529430 scopus 로고    scopus 로고
    • Safety profile of belimumab: Pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
    • D.J. Wallace, S. Navarra, and M.A. Petri Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus Lupus 22 2013 144 154
    • (2013) Lupus , vol.22 , pp. 144-154
    • Wallace, D.J.1    Navarra, S.2    Petri, M.A.3
  • 36
    • 84869072981 scopus 로고    scopus 로고
    • Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus
    • J.T. Merrill, E.M. Ginzler, and D.J. Wallace Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus Arthritis & Rheumatism 64 2012 3364 3373
    • (2012) Arthritis & Rheumatism , vol.64 , pp. 3364-3373
    • Merrill, J.T.1    Ginzler, E.M.2    Wallace, D.J.3
  • 38
    • 84879502096 scopus 로고    scopus 로고
    • Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
    • D.J. Wallace, C. Gordon, and V. Strand Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up Rheumatology 52 2013 1313 1322
    • (2013) Rheumatology , vol.52 , pp. 1313-1322
    • Wallace, D.J.1    Gordon, C.2    Strand, V.3
  • 39
    • 84889645482 scopus 로고    scopus 로고
    • Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
    • D.J. Wallace, K. Kalunian, and M.A. Petri Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Annals of the Rheumatic Diseases 2013
    • (2013) Annals of the Rheumatic Diseases
    • Wallace, D.J.1    Kalunian, K.2    Petri, M.A.3
  • 40
    • 84881480273 scopus 로고    scopus 로고
    • Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
    • M.C. Genovese, R.M. Fleischmann, and M. Greenwald Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors Annals of the Rheumatic Diseases 2012
    • (2012) Annals of the Rheumatic Diseases
    • Genovese, M.C.1    Fleischmann, R.M.2    Greenwald, M.3
  • 41
    • 84875715149 scopus 로고    scopus 로고
    • Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: A phase II, randomized, placebo-controlled trial
    • M.C. Genovese, S. Bojin, and I.M. Biagini Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial Arthritis & Rheumatism 65 2013 880 889
    • (2013) Arthritis & Rheumatism , vol.65 , pp. 880-889
    • Genovese, M.C.1    Bojin, S.2    Biagini, I.M.3
  • 42
    • 84885186752 scopus 로고    scopus 로고
    • Lupuzor/P140 peptide in patients with systemic lupus erythematosus: A randomised, double-blind, placebo-controlled phase IIb clinical trial
    • R. Zimmer, H.R. Scherbarth, O.L. Rillo, J.J. Gomez-Reino, and S. Muller Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial Annals of the Rheumatic Diseases 2012
    • (2012) Annals of the Rheumatic Diseases
    • Zimmer, R.1    Scherbarth, H.R.2    Rillo, O.L.3    Gomez-Reino, J.J.4    Muller, S.5
  • 43
    • 79959856423 scopus 로고    scopus 로고
    • Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial
    • R.F. van Vollenhoven, N. Kinnman, E. Vincent, S. Wax, and J. Bathon Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial Arthritis & Rheumatism 63 2011 1782 1792
    • (2011) Arthritis & Rheumatism , vol.63 , pp. 1782-1792
    • Van Vollenhoven, R.F.1    Kinnman, N.2    Vincent, E.3    Wax, S.4    Bathon, J.5
  • 44
    • 84856795563 scopus 로고    scopus 로고
    • Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial
    • E.M. Ginzler, S. Wax, and A. Rajeswaran Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial Arthritis Research & Therapy 14 2012
    • (2012) Arthritis Research & Therapy , vol.14
    • Ginzler, E.M.1    Wax, S.2    Rajeswaran, A.3
  • 45
    • 44849085476 scopus 로고    scopus 로고
    • The innate immune system in SLE: Type i interferons and dendritic cells
    • L. Ronnblom, and V. Pascual The innate immune system in SLE: type I interferons and dendritic cells Lupus 17 2008 394 399
    • (2008) Lupus , vol.17 , pp. 394-399
    • Ronnblom, L.1    Pascual, V.2
  • 46
    • 66449097622 scopus 로고    scopus 로고
    • Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase i trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
    • Y. Yao, L. Richman, and B.W. Higgs Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus Arthritis & Rheumatism 60 2009 1785 1796
    • (2009) Arthritis & Rheumatism , vol.60 , pp. 1785-1796
    • Yao, Y.1    Richman, L.2    Higgs, B.W.3
  • 47
    • 80053562466 scopus 로고    scopus 로고
    • Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study
    • J.T. Merrill, D.J. Wallace, and M. Petri Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study Annals of the Rheumatic Diseases 70 2011 1905 1913
    • (2011) Annals of the Rheumatic Diseases , vol.70 , pp. 1905-1913
    • Merrill, J.T.1    Wallace, D.J.2    Petri, M.3
  • 48
    • 84875697484 scopus 로고    scopus 로고
    • Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: A phase i randomized, controlled, dose-escalation study
    • M. Petri, D.J. Wallace, and A. Spindler Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study Arthritis & Rheumatism 65 2013 1011 1021
    • (2013) Arthritis & Rheumatism , vol.65 , pp. 1011-1021
    • Petri, M.1    Wallace, D.J.2    Spindler, A.3
  • 49
    • 84868144947 scopus 로고    scopus 로고
    • Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study
    • J.M. McBride, J. Jiang, and A.R. Abbas Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study Arthritis & Rheumatism 64 2012 3666 3676
    • (2012) Arthritis & Rheumatism , vol.64 , pp. 3666-3676
    • McBride, J.M.1    Jiang, J.2    Abbas, A.R.3
  • 50
    • 84873870755 scopus 로고    scopus 로고
    • Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid
    • B.R. Lauwerys, E. Hachulla, and F. Spertini Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid Arthritis & Rheumatism 65 2013 447 456
    • (2013) Arthritis & Rheumatism , vol.65 , pp. 447-456
    • Lauwerys, B.R.1    Hachulla, E.2    Spertini, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.